speb/financial-data huggingface dataset:
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -90600000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 45772000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 45772000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Change In Inventory: 129600000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Change In Payable: -437300000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Change In Receivables: 343500000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: 35800000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -21700000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Common Stock: 912700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 912700000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 13689985000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 13689985000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Common Stock Payments: -598500000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 2909483000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 2909483000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 15421000000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 4355500000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Current Assets: 13383550000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 13383550000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 11775000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 11775000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Current Debt: 3282425000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 3282425000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 3294200000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 3294200000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 8369668000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 8369668000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 42900000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 42900000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Depreciation: 557800000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 557800000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 557800000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 148800000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 557800000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 148800000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 91270000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 91270000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Diluted EPS: 18.35
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 6.88
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 1681600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 628600000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 5694000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 5694000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 100000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — EBIT: 2476400000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — EBIT: 803100000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — EBITDA: 3034200000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — EBITDA: 951900000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — End Cash Position: 45800000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -821200000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 1585625000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 1585625000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 674200000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -3100000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 176987000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 631878000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 71500000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 7567637000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 7567637000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 17766753000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 17766753000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Gross Profit: 8449300000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 2412100000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Interest Expense: 358700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 91600000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 358700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 91600000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Interest Income: 123964000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 123964000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -334400000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 122000000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Inventory: 4729283000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 4729283000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 19812411000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 19812411000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -1646300000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 224127000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 224127000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 702400000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 948109000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 948109000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 16506000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 16506000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 2840000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 2840001000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 2856507000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 2856507000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 702400000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -776100000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 43300000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 43300000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 11463349000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 11463349000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 3443000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 3443000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Minority Interests: 615000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 915000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: 0.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: -598500000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Net Debt: 6076654000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 6076654000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 2500000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Net Income: 1681600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Net Income: 628600000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 1681600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 628600000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 1681000000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 627700000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1681600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 628600000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1681600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 628600000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 2117700000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 1681000000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 627700000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Net Interest Income: -358700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -91600000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 2700000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 335500000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -73700000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -358700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -91600000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Net Other Financing Charges: -133200000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Net PPE: 11499059000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 11499059000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -1771100000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 409200000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 13058107000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 13058107000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Revenue: 1601000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 1601000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 782328000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 782328000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 43250000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 43250000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 8168000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 8168000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 3034200000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 951900000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Normalized Income: 1681600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 628600000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 2445800000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Operating Income: 2312800000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Operating Income: 784300000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Operating Revenue: 23870300000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 6767600000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 91270000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 91270000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Other Cash Adjustment Outside Changein Cash: 100000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 1000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 1000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 668900000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 668900000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: -1000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: -1000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 631878000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 631878000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Other Inventories: 50264000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: 236700000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 176200000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 176200000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: -43000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: -43000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 163600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 18700000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 4457700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 1165500000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Other Payable: 324641000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 324641000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Other Properties: 27028000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 27028000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 130279000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 130279000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 24141000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 24141000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Payables: 4688441000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Payables: 4688441000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 42896000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 42896000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 836609000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 836609000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Pretax Income: 2117700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 711500000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 37200000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Purchase Of Business: 0.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: 0.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -1771600000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 1925487000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 1925487000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 15421000000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 4355500000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 557800000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 148800000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 2360000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -776100000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Repurchase Of Capital Stock: -598500000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 5694000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 5694000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 12402659000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 12402659000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 2700000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 500000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 672393000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 849380000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Share Issued: 91270000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 91270000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Special Income Charges: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 13689985000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 13689985000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 13058107000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 13058107000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Tax Provision: 436700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 83800000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.21
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.12
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 100013000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 100013000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -551200000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Total Assets: 25746782000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 25746782000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 16529986000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 16529986000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Total Debt: 6150707000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 6150707000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 13693428000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 13693428000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Total Expenses: 21557500000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 5983300000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 12053354000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 12053354000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 12363232000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 12363232000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 3683686000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 3683686000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 31649000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 18731000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 18731000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Treasury Shares Number: 0.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Work In Process: 1167907000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 1167907000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Working Capital: 5013882000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 5013882000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Write Off: 37222000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 1577600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 5905100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 91270000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 5.91
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 3733900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 147200000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 147200000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 91270000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 5.91
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 539100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — EBIT: 596700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — EBITDA: 743900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 2171200000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 85600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 85600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Minority Interests: -624000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Net Income: 539100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 539100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 539700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 539100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 539100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 539700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -85600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -85600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 743900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 539100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Operating Income: 593600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 5905100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 3100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 1122400000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 511100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 3733900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 147200000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Tax Provision: -28600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.30
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 5311500000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 1764700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 6527900000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 3768000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 7196000000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 91270000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 4.95
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 23200000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 912700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 66500000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 245400000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 912700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 14683000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 1791400000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 4082900000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 13124200000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 10800000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 2976100000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 2986900000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 7828600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 45600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 162600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 162600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 91270000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 4.95
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 452800000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — EBIT: 681100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — EBITDA: 843700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 99100000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 12475700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 2445000000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 77000000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 77000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 4700400000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 20394700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 225400000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 12400000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 2735600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 2748000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 43300000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Minority Interest: 2900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Minority Interests: 1191000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 5645200000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Net Income: 452800000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 452800000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 451600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 452800000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 452800000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 451600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -77000000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -77000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 12475700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 14583900000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 815400000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 843700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 452800000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Operating Income: 680300000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 6527900000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 91270000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 970300000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 800100000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 13770300000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 99100000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 198500000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: -100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 1271400000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 10684300000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Other Receivables: 4600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 178900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Payables: 3768000000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 604100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 4082900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 162600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 91270000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 14683000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 14583900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 152500000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.25
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 7500000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 26122700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 17418600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 5734900000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 14685900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 5847600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 11436800000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 12998700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 3608200000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 5295600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 1779800000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 6017100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 91270000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 4.44
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 3866400000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 179500000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 179500000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 91270000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 4.44
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 405400000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — EBIT: 383100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — EBITDA: 562600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 2150700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 92900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 92900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Minority Interests: -116000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Net Income: 405400000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 405400000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 405500000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 405400000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 405400000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 405500000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -92900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -92900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 562600000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 405400000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Operating Income: 370900000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 6017100000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 12300000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 1268700000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 290200000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 3866400000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 179500000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Tax Provision: -115300000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.30
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 5646200000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: 0.00
AARTIDRUGS.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 0.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — +Operating Expense: 7043600000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 1921200000.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — +Total Revenue: 25653100000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 7203000000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 4778800000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 4778800000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 8298700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 8298700000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 91270000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 6.05
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 45800000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -1733200000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 18100000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 18100000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 912700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 912700000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 72700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 72700000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 242800000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 242800000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -181700000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -178500000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Change In Payable: 236300000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -700000000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -642200000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 26900000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Common Stock: 912700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 912700000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 15488600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 15488600000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Common Stock Payments: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 2138100000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 2138100000.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 16187200000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 4504200000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Current Assets: 14677700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 14677700000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 9500000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 9500000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Current Debt: 3179600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 3179600000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 3189100000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 3189100000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 9222600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 9222600000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 81200000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 81200000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Depreciation: 669700000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 669700000.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 669700000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 180400000.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 669700000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 180400000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 91270000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 6.05
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 1949200000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 551900000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 0.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — EBIT: 2446100000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — EBIT: 785200000.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — EBITDA: 3115800000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — EBITDA: 965600000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — End Cash Position: 72700000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -774400000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 802200000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -200000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 164300000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 164300000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 12837800000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 12837800000.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — Gross Profit: 9465900000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 2698800000.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — Interest Expense: 337100000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 81600000.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 337100000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 81600000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -323000000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 11700000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Inventory: 4907800000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 4907800000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 21236900000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 21236900000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -1734100000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 273100000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 273100000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Issuance Of Debt: 430300000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 8600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 8600000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 2568700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 2568700000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 2577300000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 2577300000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Long Term Debt Issuance: 430300000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -567800000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 45500000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 45500000.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 3646000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 3646000.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — Minority Interests: -203000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Minority Interests: -655000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Net Business Purchase And Sale: 0.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2026-03-31) — Net Debt: 5675600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 5675600000.00
AARTIDRUGS.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -4700000.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — Net Income: 1949200000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Net Income: 551900000.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 1949200000.00
AARTIDRUGS.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 551900000.00
AARTIDRUGS.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 1949400000.00